Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Portfolio evolution helps Danaher post "solid" Q3

This article was originally published in Clinica

Executive Summary

Jefferies analyst Brandon Couillard has raised his 2014 earnings forecast for Danaher to $3.80 per share, from $3.75, on the back of a “solid” third quarter. He noted that the company’s Q3 “core EPS of $0.84 was $0.01 ahead of consensus on better than expected core revenue growth [3% vs his estimate of 2.5%] and profitability experiences.” Danaher’s Q3 sales grew 6% to $4.67bn on a reported basis, up 3% at constant currency. The company has benefited from “portfolio repositioning efforts,” the analyst added, and “expansion in its life sciences & diagnostics and dental franchises helped mitigate the effects of muted trends in certain industrial-oriented areas, which appear to be stabilizing.” Danaher was recently boosted by the approval of a key troponin test, used as a marker of heart attack, developed by its Beckman Coulter subsidiary (, 27 September 2013). There has also been speculation that Danaher could be in the running to acquire Johnson & Johnson’s Ortho Clinical Diagnostics unit (, 11 September 2013).






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts